1.Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition
Masato NAGINO ; Satoshi HIRANO ; Hideyuki YOSHITOMI ; Taku AOKI ; Katsuhiko UESAKA ; Michiaki UNNO ; Tomoki EBATA ; Masaru KONISHI ; Keiji SANO ; Kazuaki SHIMADA ; Hiroaki SHIMIZU ; Ryota HIGUCHI ; Toshifumi WAKAI ; Hiroyuki ISAYAMA ; Takuji OKUSAKA ; Toshio TSUYUGUCHI ; Yoshiki HIROOKA ; Junji FURUSE ; Hiroyuki MAGUCHI ; Kojiro SUZUKI ; Hideya YAMAZAKI ; Hiroshi KIJIMA ; Akio YANAGISAWA ; Masahiro YOSHIDA ; Yukihiro YOKOYAMA ; Takashi MIZUNO ; Itaru ENDO
Chinese Journal of Digestive Surgery 2021;20(4):359-375
The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version in 2014. In this 3rd version, clinical questions (CQs) were proposed on six topics. The recommendation, grade for recommendation, and statement for each CQ were discussed and finalized by an evidence-based approach. Recommendations were graded as grade 1 (strong) or grade 2 (weak) according to the concepts of the grading of recommendations assessment, development, and evaluation system. The 31 CQs covered the six topics: (1) prophylactic treatment, (2) diagnosis, (3) biliary drainage, (4) surgical treatment, (5) chemotherapy, and (6) radiation therapy. In the 31 CQs, 14 recommendations were rated strong and 14 recommendations weak. The remaining three CQs had no recommendation. Each CQ includes a statement of how the recommendations were graded. This latest guideline provides recommendations for important clinical aspects based on evidence. Future collaboration with the cancer registry will be key for assessing the guidelines and establishing new evidence.
2.Safety and Recipient Satisfaction of Propofol Sedation in Outpatient Endoscopy: A 24-Hour Prospective Investigation Using a Questionnaire Survey
Yoshihide KANNO ; Tetsuya OHIRA ; Yoshihiro HARADA ; Shinsuke KOSHITA ; Takahisa OGAWA ; Hiroaki KUSUNOSE ; Yoshiki KOIKE ; Taku YAMAGATA ; Toshitaka SAKAI ; Kaori MASU ; Keisuke YONAMINE ; Kazuaki MIYAMOTO ; Megumi TANAKA ; Tomohiro SHIMADA ; Fumisato KOZAKAI ; Kazuki ENDO ; Haruka OKANO ; Daichi KOMABAYASHI ; Takeshi SHIMIZU ; Shohei SUZUKI ; Kei ITO
Clinical Endoscopy 2021;54(3):340-347
Background/Aims:
The aim of this study was to evaluate the safety of sedation with propofol as an alternative to benzodiazepine drugs in outpatient endoscopy.
Methods:
In this prospective study, examinees who underwent outpatient endoscopy under propofol sedation and submitted a nextday questionnaire with providing informed consent were evaluated. Periprocedural acute responses, late adverse events within 24 hours, and examinee satisfaction were evaluated.
Results:
Among the 4,122 patients who received propofol in the 17,978 outpatient-based endoscopic examinations performed between November 2016 and March 2018, 2,305 eligible examinees (esophagogastroduodenoscopy for 1,340, endoscopic ultrasonography for 945, and total colonoscopy for 20) were enrolled, and their responses to a questionnaire were analyzed. The mean propofol dose was 69.6±24.4 mg (range, 20–200 mg). Diazepam, midazolam, and/or pentazocine in combination with propofol was administered to 146 examinees. Mild oxygen desaturation was observed in 59 examinees (2.6%); and mild bradycardia, in 2 (0.09%). Other severe reactions or late events did not occur. After eliminating 181 invalid responses, 97.7% (2,065/2,124) of the patients desired propofol sedation in future examinations.
Conclusions
Propofol sedation was found to be safe—without severe adverse events or accidents—for outpatient endoscopy on the basis of the patients’ next-day self-evaluation. Given the high satisfaction level, propofol sedation might be an ideal tool for painless endoscopic screening.
3.Safety and Recipient Satisfaction of Propofol Sedation in Outpatient Endoscopy: A 24-Hour Prospective Investigation Using a Questionnaire Survey
Yoshihide KANNO ; Tetsuya OHIRA ; Yoshihiro HARADA ; Shinsuke KOSHITA ; Takahisa OGAWA ; Hiroaki KUSUNOSE ; Yoshiki KOIKE ; Taku YAMAGATA ; Toshitaka SAKAI ; Kaori MASU ; Keisuke YONAMINE ; Kazuaki MIYAMOTO ; Megumi TANAKA ; Tomohiro SHIMADA ; Fumisato KOZAKAI ; Kazuki ENDO ; Haruka OKANO ; Daichi KOMABAYASHI ; Takeshi SHIMIZU ; Shohei SUZUKI ; Kei ITO
Clinical Endoscopy 2021;54(3):340-347
Background/Aims:
The aim of this study was to evaluate the safety of sedation with propofol as an alternative to benzodiazepine drugs in outpatient endoscopy.
Methods:
In this prospective study, examinees who underwent outpatient endoscopy under propofol sedation and submitted a nextday questionnaire with providing informed consent were evaluated. Periprocedural acute responses, late adverse events within 24 hours, and examinee satisfaction were evaluated.
Results:
Among the 4,122 patients who received propofol in the 17,978 outpatient-based endoscopic examinations performed between November 2016 and March 2018, 2,305 eligible examinees (esophagogastroduodenoscopy for 1,340, endoscopic ultrasonography for 945, and total colonoscopy for 20) were enrolled, and their responses to a questionnaire were analyzed. The mean propofol dose was 69.6±24.4 mg (range, 20–200 mg). Diazepam, midazolam, and/or pentazocine in combination with propofol was administered to 146 examinees. Mild oxygen desaturation was observed in 59 examinees (2.6%); and mild bradycardia, in 2 (0.09%). Other severe reactions or late events did not occur. After eliminating 181 invalid responses, 97.7% (2,065/2,124) of the patients desired propofol sedation in future examinations.
Conclusions
Propofol sedation was found to be safe—without severe adverse events or accidents—for outpatient endoscopy on the basis of the patients’ next-day self-evaluation. Given the high satisfaction level, propofol sedation might be an ideal tool for painless endoscopic screening.